VEGF

Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

HARMONi-6 marks the first phase 3 trial in which a regimen has beaten the combination of a PD-1 inhibitor and chemotherapy on PFS in first-line NSCLC.

Angus Liuu Oct 19, 2025 10:45am

Graphic of a fork in the road with arrows pointing in either direction

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm

Merck CMO talks Akeso, Summit's Keytruda head-to-head win

Jun 3, 2024 12:00pm

Summit and Akeso deliver Keytruda-topping results in NSCLC

May 31, 2024 11:00am

Novartis targets longer Beovu dosing interval in DME

Aug 17, 2021 10:15am

Novartis caps 3 Beovu trials on safety concerns

Jun 1, 2021 11:41am